Pfizer Depo-subQ Provera 104 Will Launch In May With Endometriosis Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
The new formulation has greater contraceptive efficacy and less hormone than Depo-Provera, Pfizer says. Labeling carries "black box" warnings on loss of bone mineral density; Pfizer notes that, in clinical trials, depo-subQ provera 104 had less decrease in BMD than endometriosis-pain comparator Lupron Depot.
You may also be interested in...
Depo-Provera "Black Box" Urges Limited Long-Term Use
Pfizer's injectable contraceptive should be used longer than two years "only if other birth control methods are inadequate," the "black box" states. Warning regarding bone loss is based on two five-year Phase IV studies in adolescents and adults.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).
No More NASHing Of Teeth: Madrigal’s Resmetirom Approval Ends Years Of Industry Frustration
US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.